Composition and method for treating nucleic acid-related eye disease

1. A method for the treatment of a nucleic acid-related eye disease, comprising administering an effective amount of a composition to the surface of the eye to remove nucleic acid from the surface of the eye, wherein the composition comprises a nuclease and an ophthalmic excipient; wherein the nuclease is a DNase, an RNase or a combination thereof, and wherein the composition does not contain an antibiotic.

2. The method of claim 1 , wherein the ocular surface of the eye contains a tear film.

3. The method of claim 2 , wherein the tear film is a biofilm or a mucoid film.

4. The method of claim 3 , wherein the biofilm or mucoid film contains nucleic acid.

5. The method of claim 4 , wherein the nucleic acid is extracellular nucleic acid.

6. The method of claim 4 , wherein the nucleic acid is DNA, RNA, or a combination thereof.

7. The method of claim 1 , wherein the effective amount of the composition contains between 5 ng/ml and 3 mg/ml of the nuclease.

8. The method of claim 7 , wherein the effective amount of the composition contains between 1 mg/ml and 3 mg/ml of the nuclease.

9. The method of claim 1 , wherein the nucleic acid-related eye disease is selected from the group consisting of dry eye disease, lamellar keratitis, contact lens-associated keratitis, endophthalmitis, infectious crystalline keratopathy, ocular cicatricial pemphigoid (OCP), keratoconjunctivitis sicca (KCS), Sjogren syndrome (SS), Sjogren syndrome associated keratoconjunctivitis sicca, non-Sjogren syndrome associated keratoconjunctivitis sicca, keratitis sicca, sicca syndrome, xerophthalmia, tear film disorder, decreased tear production, aqueous tear deficiency (ATD), and meibomian gland dysfunction (MGD).